In this work, we report that the protective effect of baricitinib against death is most pronounced in obese patients which may be significant to immunopathogenesis considerations and therapy selection for disease.
← all excerpts
Pronounced benefits of JAK inhibition with baricitinib in COVID-19 pneumonia in obese but not lean subjects.
1
—
—